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COVID-19 Clinical Guidance  
For the Cardiovascular Care Team 
 
Note: COVID-19 is a quickly evolving public health emergency. The guidance provided in 
this document is based on the best available published information and expert evaluation.  
This document is intended to supplement, not supersede, relevant guidance from the 
Centers for Disease Control and Prevention, state and local health authorities, and your 
institution’s infectious disease containment, mitigation, and response plan. 
To best serve your patients, protect yourself first! This is especially true for cardiovascular 
care team professionals that will be on the front line of the COVID-19 response. Use masks, 
gloves, and other personal protective equipment with discipline. Wash hands often. 
Decontaminate surfaces including stethoscope, cellular phones, computer peripherals, and 
other devices frequently. 
 
Current COVID-19 Clinical Context 
• The overall case fatality rate (CFR) of COVID-19 based on published reports remains 
low at 2.3%, with data indicating lower overall Chinese mortality outside of the 
outbreak epicenter in Hubei, Chinai 
• Beyond China, real-time reporting indicates CFRs between 2.7% (Iran) and 0.5% 
(South Korea); however, this information is provisional and likely to changeii 
• More than 80% of infected patients experience mild symptoms and recover without 
intensive medical interventioni 
• However, morbidity and mortality increase significantly with age, rising to 8.0% 
among patients 70-79 and 14.8% in patients over 80 in large-scale Chinese case 
reportingi 
• Published case reports from the Chinese Centers for Disease Control indicate 
patients with underlying comorbid conditions have a heighted risk for contracting 
COVID-19 and a worse prognosis; depending on the report, between 25% and 50% 
of COVID-19 patients present with underlying conditionsi,iii 
• Case fatality rates for comorbid patients are materially higher than the average 
population:i 
o Cancer: 5.6% 
o Hypertension: 6.0% 
o Chronic respiratory disease: 6.3% 
o Diabetes: 7.3% 
o Cardiovascular disease: 10.5% 
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Acute Cardiac Complications of COVID-19 
• In a recent case report on 138 hospitalized COVID-19 patients, 16.7% of patients 
developed arrhythmia and 7.2% experienced acute cardiac injury, in addition to 
other COVID-19 related complicationsiv 
• Published and anecdotal reports indicate cases of acute onset heart failure, 
myocardial infarction, myocarditis, and cardiac arrest; as with any acute illness, 
higher cardiometabolic demand can precipitate cardiac complications 
• Current reporting does not yet describe prevalence of cardiac complications in CVD-
naïve versus cardiac comorbid patients 
• Cardiac complications of COVID-19 are approximately commensurate with SARS, 
MERS, and influenza analogs 
• Cardiologists should be prepared to assist other clinical specialties in managing 
cardiac complications in severe cases of COVID-19 
• Critical care and cardiology teams should confer to guide care for patients requiring 
extracorporeal circulatory support with veno-venous (V-V) versus veno-arterial (V-A) 
ECMO 
• Patients demonstrating heart failure, arrhythmia, ECG changes or cardiomegaly 
should have echocardiography 
 
COVID-19 Implications For Patients With Underlying 
Cardiovascular Conditions 
• Make plans for quickly identifying and isolating cardiovascular patients with COVID-
19 symptoms from other patients, including in the ambulatory setting 
• Patients with underlying cardiovascular disease are at higher risk of contracting 
COVID-19 and have a worse prognosis 
• It is reasonable to advise all cardiovascular patients of the potential increased risk 
and to encourage additional, reasonable precautions in accordance with CDC 
guidance 
• It is important for patients with CVD to remain current with vaccinations, including 
the pneumococcal vaccine given the increased risk of secondary bacterial infection 
with COVID-19; CVD patients should be vaccinated against influenza in accordance 
with current ACC/AHA guidelines 
• In geographies with active COVID-19 outbreaks, it may be reasonable to substitute 
telephonic or telehealth visits for in-person routine visits for stable CVD patients to 
avoid possible nosocomial COVID-19 infection; planning for emergency telehealth 
protocols should begin now 
• It is reasonable to triage COVID-19 patients according to underlying cardiovascular, 
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• Providers are cautioned that classic symptoms and presentation of AMI may be 
overshadowed in the context of COVID-19, resulting in underdiagnosis 
• For patients with heart failure or volume overload conditions, copious fluid 
administration for viral infection should be used cautiously and carefully monitored 
• General immunological health remains important for both providers and patients, 
including eating well, sleeping and managing stress 
 
Cardiac-specific Preparedness Recommendations For COVID-19 
• In some settings, the cardiovascular care team (including physicians, nurses, 
technicians, etc.) may have limited training and experience with the acute 
management of pandemic disease; the routine transmission of COVID-19 to 
healthcare workers suggests that everyday infectious disease mitigation 
precautions are insufficient and healthcare workers in outbreak geographies must 
be prepared to adopt personal protection measures 
• Protocols for the diagnosis, triage, isolation, and management of COVID-19 patients 
with cardiovascular complications and/or cardiovascular patients with COVID-19 
should be developed in detail and rehearsed; CV-specific plans should be developed 
in collaboration with hospital-wide infectious disease response plans and in close 
collaboration with other medical specialties 
• Cardiovascular care team members with limited experience and/or training in 
personal protective equipment (PPE) donning, usage, and doffing should be trained 
now in accordance with CDC guidance 
• Specific protocols should be developed for the management of AMI in the context of 
a COVID-19 outbreak, both for patients with and without a COVID-19 diagnosis 
o Particular emphasis should be placed on acute PCI and CABG, including 
protocols to limit catheterization lab and OR personnel to a required 
minimum, pre-determining requirements for enhanced personal protection, 
and assessing post-procedural sterilization sufficiency 
o In extreme circumstances, clinical leadership may need to assess the risk-
benefit ratio of acute MI intervention (given limited data on primary PCI 
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